Ganymed Pharmaceuticals Ag

Johannes Gutenberg-Universität Mainz

Biontech Ag

Ganymed Pharmaceuticals Gmbh

Tron—translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Johannes Gutenberg Universität

Other

Astellas Pharma Gmbh

Biontech Se

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Biontech Rna Pharmaceuticals Gmbh

Biontech Protein Therapeutics Gmbh

Tron—translationale Onkologie An Der Univresitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh

UniversitÄtsmedizin Der Johannes Gutenberg-Universitat Mainz

Johannes Gutenberg-universität Mainz, Vertreten Durch Den Präsidenten

Michael Koslowski

Ugur Sahin

Ozlem Tureci

Özlem Türeci

Korden Walter

Maria Kreuzberg

Dirk Usener

Gerd Helftenbein

Stefan Woll

Bernd Hubner

Michael Erdeljan

Volker Schlüter

Philippe Thiel

Sandra Schneider

Michael Weichel

Thomas Michael Hiller

Thorsten Klamp

Jens Schumacher

Sylvia Luxen

Sebastian Kreiter

Mustafa Diken

Rita Mitnacht-Kraus

Harald-Gerhard Geppert

Tana Omokoko

Jan Diekmann

John Christopher Castle

Bernhard Renard

Gabriela-Elena Oprea

Cedrik Britten

Johannes Hendrikus De Graaf

Stefan Fritz

Martin Löwer

Stefan Wöll

Matthias Grimmler

Christoph Hartmann

Ozlem Türeci

Stephan Fritz

Rita Mitnachtkraus

Ugar Sahin

Öezlem Tüereci

Özlem Tureci

Walter Korden

Stefanie Hubich

Diana Barea Roldàn

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies for treatment of cancer expressing claudin 6

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies specific for claudin 6 (CLDN6)

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.

Methods and compositions for diagnosis and treatment of cancer

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

Individualized vaccines for cancer

The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.

Cancer therapy using CLDN6 target-directed antibodies in vivo

The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

Monoclonal anti-GT 468 antibodies for treatment of cancer

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Tumor vaccination involving a humoral immune response against self-proteins

The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.

Genetic products differentially expressed in tumors and the use thereof

The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

Identification of surface-associated antigens for tumor diagnosis and therapy

The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Identification of tumor-associated markers for diagnosis and therapy

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Growing community of inventors

Mainz, Germany

Michael Koslowski